Special Issue

Topic: Interventional Radiology in Treatment of Hepatocellular Carcinoma

ISSN 2454-2520 (Online) 2394-5079 (Print)

Submission deadline: 1 Jul 2022

Guest Editor(s)

David C. Madoff, MD, FSIR, FACR, FCIRSE

Professor of Radiology & Biomedical Imaging and Medical Oncology; Vice Chair for Clinical Research, Radiology & Biomedical Imaging; Section Chief, Interventional Radiology; Co-Director of Yale Interventional Oncology Research Lab from Yale School of Medicine, New Haven, CT, USA.

Lucatelli Pierleone, MD, PhD, EBIR, FCIRSE

Department of Radiology, Vascular and Interventional Radiology Unit, Sapienza University of Rome, Rome, Italy.

Special Issue Introduction

This Special Issue edited by Dr. David C. Madoff and Dr. Lucatelli Pierleone on "Interventional Radiology in Treatment of Hepatocellular Carcinoma" invites original or review manuscripts, perspectives, opinions, and commentary, etc. on different aspects, including but not limited to:

1. BCLC 2022 – How will it impact the use of liver-directed therapies?
2. Artificial intelligence and its role in guiding liver-directed therapy for HCC: is it ready for prime time?
3. Imaging after liver-directed therapy: a 2022 update from the LI-RADS Therapeutic Response Working Group
4. Image-guided percutaneous strategies to improve the resectability of HCC: portal vein embolization, liver venous deprivation, or radiation lobectomy?
5. Ablation for early-stage HCC: should it be used as first-line therapy?
6. Robotics in IR: how can this help in the treatment of HCC?
7. Transarterial therapies for HCC: how to decide the best option for a specific patient?
8. Novel strategies to improve results of transarterial therapy: balloon occlusion and beyond
9. What's new in advanced imaging technology to guide transarterial therapies?
10. Combining liver-directed therapy with immune-oncology for HCC: is there a real benefit?